Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Rocket Announces Appointment of Aaron Ondrey as CFO and Additional Updates
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Rocket Pharma is getting ready to light up national landmarks on Thursday as part of its annual rare disease awareness effort, but this year the event is even more meaningful as Rocket awaits an FDA decision on its first drug candidate.
Is Rocket Pharmaceuticals Inc Stock at the Top of the Biotechnology Industry?
The FDA’s decision on Rocket Pharmaceuticals’ autologous gene therapy for a rare white blood cell disorder has been pushed back by three months to June 30 to give the agency more time to review its chemistry manufacturing and controls.
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)